Michael Grainger

Michael Grainger is an associate in Goodwin’s Technology and Life Sciences groups in London. Mike advises clients on a broad range of corporate matters, with a focus on transactions in the life sciences, healthcare, and technology sectors. He has particular experience advising on private equity and venture capital investments/exits, mergers and acquisitions, corporate finance, and re-organisations as well as general corporate matters.

Exits

• M&A Transactions
  • Advising KaNDy Therapeutics on its sale to Bayer for $425 million upfront with up to $450 million in development milestone payments and triple digit millions in commercial milestones.  
  • Advising Enterprise Therapeutics Ltd on the demerger and subsequent acquisition of its TMEM16A potentiator portfolio by Roche for an upfront consideration of £75 million and significant potential milestone payments.
  • Scottish Equity Partners-backed Dotmatics Limited on its sale to Insightful Science, an Insight Partners portfolio company providing software to the global life sciences community.
  • Advising Symprove Holdings Limited and its shareholders, on the sale of 100% of its share capital, to bd-capital for a total initial consideration of approximately £40 million.
  • Arctos Medical AG and its shareholders on the sale of 100% of its share capital to Novartis
  • Ares on the provision of their financing package in support of Midlothian Capital Partners to acquire Park Leisure.*
  • The selling shareholders in Ziarco Group Limited in connection with the sale of the company to Novartis.*
  • Mid Europa Partners on the acquisition of the entire issued share capital of Profi Rom Food S.R.L from Enterprise Investors.*
    IPO
    
    
• IPO
  • Vaccitech Limited on its $110 million initial public offering.
  • Advising Bicycle Therapeutics plc on its IPO on Nasdaq in the U.S.

VC Transactions

• Investor
  • Advising Y Combinator’s Continuity growth fund as lead investor on a Series F investment of £113 million ($144 million) into Monzo Bank Limited.
  • Advising Lakestar on its series A investments into Yapily Ltd and Uncapped Ltd.
  • Representing the new investors BioDiscovery 5 PFCI (advised by Andera Partners) and LSP 6 Cooperatief UA (Life Science Partners) on the £65 million Series B equity financing round of Artios Pharma Limited.
  • Representing the lead investor LSP Health Economics Fund 2 (advised by Life Science Partners) on the $28 million series C equity financing round of Lumeon Limited.
  • Representing the new investors BioDiscovery 5 PFCI (advised by Andera Partners) and LSP 6 Cooperatief UA (Life Science Partners) on the £65 million Series B equity financing round of Artios Pharma Limited.
  • InMotion Ventures (part of the Jaguar Land Rover group) — Advised on various transactions including its investments into Arc.
    
    
• Company
  • Vaccitech Limited in its $168 million Series B financing.
  • Advising NodThera Limited on its $55 million Series B equity financing.
  • Advising Exscientia Limited (an AI-driven drug discovery company) on its $26 million series B equity financing round. The Investors were Celgene Corporation, GT Healthcare Capital Partners and Evotec AG.
  • Brytlyt Limited, a company that is developing and commercializing GPU-accelerated data processing technology, on its completion of a £3.2 million Series A funding round led by Amadeus V Technology Fund LP and Finch Capital Fund II Cooperatief U.A.
  • Bicycle Therapeutics Limited on its £40 million Series B equity financing round, led by Vertex Global Fund I alongside Cambridge Innovation Capital and Longwood Fund, with existing investors including Novartis Venture Fund, SR One, and SVLS also participating in the round.*

* Denotes experience prior to joining Goodwin.